BioNexus Gene Lab Corp. (BGLC)
NASDAQ: BGLC · Real-Time Price · USD
2.540
+0.290 (12.89%)
Mar 17, 2026, 4:00 PM EDT - Market closed

BioNexus Gene Lab Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Equivalents
2.894.385.932.122.122.79
Cash & Short-Term Investments
2.894.385.932.122.122.79
Cash Growth
-30.03%-26.17%179.84%-0.24%-23.81%224.50%
Accounts Receivable
1.521.380.82.873.364
Other Receivables
0.20.290.180.060.080.02
Total Trade Receivables
1.721.660.982.933.444.02
Inventory
1.011.391.140.981.521.18
Other Current Assets
----0.07-
Total Current Assets
5.637.438.056.027.157.99
Net Property, Plant & Equipment
1.761.741.651.571.681.85
Long-Term Investments
0.241.271.71.150.750.28
Total Assets
7.6210.4311.48.749.5710.12
Accounts Payable
0.561.791.581.962.083.27
Current Portion of Leases
0.060.050.030.020.040.05
Unearned Revenue
0.010.1-0.020.11-
Other Current Liabilities
0.050.020.01-0.10.06
Total Current Liabilities
0.681.951.6322.333.37
Long-Term Leases
0.130.160.10.040.040.08
Other Long-Term Liabilities
--0.010.030.030
Total Long-Term Liabilities
0.130.160.110.070.070.08
Total Liabilities
0.82.111.742.082.393.45
Common Stock
17.3317.3317.1910.9310.7810.78
Additional Paid-in Capital
-5.01-5.01-5.01-5.01-5.01-5.01
Accumulated Other Comprehensive Income
-0.11-0.56-0.68-0.41-0.10.13
Retained Earnings
-5.2-3.44-1.841.161.510.76
Shareholders' Equity
6.828.329.666.677.186.66
Total Liabilities & Equity
7.6210.4311.48.749.5710.12
Total Debt
0.180.210.130.060.080.12
Net Cash (Debt)
2.714.175.82.062.052.66
Net Cash Growth
-34.94%-28.11%181.07%0.74%-23.17%246.17%
Net Cash Per Share
0.120.230.361.431.443.11
Book Value
6.828.329.666.677.186.66
Book Value Per Share
0.310.470.614.635.037.77
Tangible Book Value
6.828.329.666.677.186.66
Tangible Book Value Per Share
0.310.470.614.635.037.77
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q